Vincristine

Sulfate is the active ingredient.

Acute lymphoblastic leukemia (ALL)

Hodgkin's lymphoma

NonHodgkin's lymphoma

Neuroblastoma

Rhabdomyosarcoma

Wilms' tumor

Other solid tumors (in combination with other chemotherapeutic agents)

Unicristin 1mg/1ml Inj (Vincristine) is a vinca alkaloid antineoplastic agent. It inhibits microtubule assembly, preventing cell division and ultimately leading to cell death. This effect is particularly pronounced in rapidly dividing cancer cells.

Store at controlled room temperature (20°C to 25°C) (68°F to 77°F). Protect from light. Dispose of unused medication properly according to local regulations. Never flush down the toilet.

Dosage is determined by the physician based on the patient's weight, age, overall health, and the specific cancer being treated.

It's typically administered intravenously (IV) by a healthcare professional.

Self-administration is not permitted.

Peripheral neuropathy (numbness, tingling, pain in the hands and feet)

Nausea and vomiting

Constipation

Hair loss

Mouth sores

Fatigue

Loss of appetite

Muscle weakness

Heart problems (rare but serious)

Alcohol Consumption

Alcohol consumption should be discussed with your doctor, as it may interact with the medication or worsen side effects.



While Driving or operating Machinery

Vincristine can cause fatigue, dizziness, and peripheral neuropathy which may impair coordination. Avoid driving or operating machinery if affected.



Pregnant & Breastfeeding Women

Vincristine is contraindicated in pregnancy and breastfeeding women due to its potential for severe harm to the fetus or infant.



Children

Dosage is carefully adjusted for children based on their weight and the specific cancer being treated. Requires close monitoring.



Kidney

Kidney function should be monitored, as vincristine is primarily eliminated by the kidneys. Dose adjustments may be necessary in patients with impaired renal function.



Liver

Liver function should be monitored, as vincristine metabolism can be affected by liver impairment. Dose adjustments may be necessary.

Physician's Desk Reference (PDR)

National Cancer Institute (NCI) website

Your Oncologist